Shopping Cart
- Remove All
![TargetMol](https://newstatic.targetmol.com/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Backorder | |
5 mg | Inquiry | Backorder |
Description | Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody that targets the CD4 molecule and effectively inhibits T-cell receptor (TCR) signal transduction. It is used in the research of rheumatoid arthritis, psoriasis, melanoma, cutaneous, and peripheral T-cell lymphoma [1]. |
In vitro | Zanolimumab, at concentrations of 10 and 100 ng/mL, effectively induces cytotoxicity in CD4+ T cells, demonstrating enhanced activity on the CD45RO+ subset compared to the CD45RA+ subset. Additionally, within a range of 1-10,000 ng/mL, the compound dose-dependently and through its Fc region, decreases CD4 expression on both purified primary CD4+ T cells and SUP-T1 T cells. Furthermore, Zanolimumab potently suppresses T-cell proliferation initiated by T-cell receptor (TCR) stimulation, as observed with both tetanus toxin and anti-CD3 challenges, and inhibits TCR signal transduction within a 0-30 minute timeframe. |
Alias | Anti-Human CD4 Recombinant Antibody |
Cas No. | 652153-01-0 |
Storage |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.